Tablet Health review

Tablet Health's best disclosure is a rare one: it names four partner compounding pharmacies with street addresses and phone numbers, one with an NPI number and a stated 503A license, so you can check them yourself. It is LegitScript-certified under a specific number, and it offers NAD⁺ in two routes, injection and nasal spray. The problem for an NAD⁺ shopper is that neither NAD⁺ page shows a price — its published figures all belong to its GLP-1 line. Around that sit gaps worth weighing: no state list, nobody named clinically, and a 2026 copyright.

Tablet Health (Tablet, LLC, trading with a Tablet Telehealth Corp footer) is a direct-to-consumer telehealth platform selling compounded semaglutide and tirzepatide in both injectable and oral forms, sildenafil and tadalafil for ED, and NAD⁺ in two routes — an NAD⁺ injection and an NAD⁺ nasal spray. It is LegitScript-certified under certificate 70456 and names four partner compounding pharmacies: The Pharmacy Hub in Miami, Epiq Scripts in Richardson, Texas — with an NPI number and a stated 503A state license — Dr. TelX LLC in Kennewick, Washington, and Emerad Compounding Pharmacy in Tampa. A pharmacy of its own in Queens, New York is described as opening soon.

Quiz-led intake with consultations stated to be conducted by US-licensed healthcare providers, and a cancel-anytime model with no long-term commitment advertised. The pharmacy disclosure is genuinely the standout: four facilities named with full addresses and phone numbers, one with an NPI and a stated 503A designation, is a level of traceability most of this category refuses, and it is checkable in minutes. LegitScript certification under a specific number adds a real, independently verifiable check on advertising and pharmacy conduct. What calls for caution is everything on the human side. No founder, chief executive, medical director or pharmacist-in-charge is named anywhere on the site or in its terms. No state list is published, so eligibility is only discovered by completing the quiz. Its own New York pharmacy is described as opening soon, meaning all dispensing currently runs through the external partners. Support is email-only with no published phone number. The copyright dates to 2026, so there is no multi-year track record. And its self-reported customer counts differ between sections of the same page, which is a small thing that tells you something about editorial control, so don't lean on either figure.

Published for GLP-1s, absent for NAD⁺. Its weight-loss line carries clear starting anchors: oral semaglutide from $179 a month, compounded semaglutide from $199, oral tirzepatide from $199 and compounded tirzepatide from $299. Its NAD⁺ injection and NAD⁺ nasal spray pages carry no price at all, and no dose or mg strength is stated for either route. It prices GLP-1s but not NAD⁺, so ask for the NAD⁺ price before you start. There is a second problem behind the missing number: even on the GLP-1 side, per-dose pricing is gated behind the intake quiz and only the starting anchors are public, so a patient titrating upward cannot see what that costs before enrolling. Expect the same opacity on NAD⁺. Cancel-anytime is advertised, which limits the downside of finding out, but ask for the recurring NAD⁺ charge and the dose it covers in writing before you complete an intake.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Four named partner pharmacies is the strongest part of this listing — none of the four had an FDA warning letter when this review was written — and compounded sterile products are still not reviewed by the FDA for purity and potency the way approved drugs are. One regulatory point a buyer should hold: the FDA ended its enforcement discretion for compounded tirzepatide and semaglutide in 2025, so the legal basis for ongoing compounded GLP-1 supply now rests on each pharmacy's patient-specific 503A exemption, which is not something we can independently verify. On the evidence, both NAD⁺ routes Tablet offers sit at the weak end. Injected NAD⁺ has no controlled human outcome trials at all, and the intranasal route has less pharmacokinetic support still — there is no published human data establishing what fraction of an intranasal dose reaches systemic circulation, let alone what it does there. The NAD⁺ forms with human trial data are the oral precursors nicotinamide riboside and nicotinamide mononucleotide, and what those trials reliably demonstrate is a raised blood NAD⁺ level rather than a clinical outcome. Individual results vary.